Mechanisms of action and clinical effects of vortioxetine

Petrova N.N.; Mukhin A.A.

doi:https://doi.org/10.17116/jnevro202212206284

Close metadata

Recommended articles:

Efficacy and safety of topical antibiotic therapy in patients with acute external bacterial otitis: results of a retrospective study. Russian Bulletin of Otorhinolaryngology. 2024;(6):24-27

Effectiveness and tolerability of agomelatine (Valdoxan) in the treatment of depression after COVID-19 (TELESFOR study). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):90-98

Abstract:

The opinion article is devoted to the analysis of a large-scale comprehensive systematic review of relevant and practically oriented studies of vortioxetine use in depression for the period to 2020. The mechanisms of multimodal action, issues of efficacy and safety of the drug, including direct procognitive effects, effects on anhedonia, anxiety, sleep disorders, analgesic and anti-inflammatory effects are highlighted. An increase in the efficacy of vortioxetine when the dose is increased to 20 mg/day is emphasized. Prospective directions for antidepressant research are outlined.

Keywords:

vortioxetine

mechanisms of action

clinical efficacy

tolerability

Authors:

Petrova N.N.

Saint-Petersburg State University

ORCID: 0000-0003-4096-6208

Mukhin A.A.

Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine

ORCID: 0000-0002-2665-8607

Received:

12.04.2022

Accepted:

14.04.2022

Close metadata

References:

De Diego-Adeliño J, Crespo JM, Mora F, et al. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf. 2022;21(5):673-690. https://doi.org/10.1080/14740338.2022.2019705
Chen G, Højer AM, Areberg J, et al. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018;57(6):673-686.
Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43-57.
Nackenoff AG, Simmler LD, Baganz NL, et al. Serotonin transporter-independent actions of the antidepressant vortioxetine as revealed using the SERT Met172 mouse. ACS Chem Neurosci. 2017;8(5):1092-1100.
Li Y, Raaby KF, Sánchez C, et al. Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behav Brain Res. 2013;256:520-528.
Hlavacova N, Li Y, Pehrson A, et al. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:332-338.
Riga MS, Sánchez C, Celada P, et al. Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: focus on glutamatergic and GABAergic neurotransmission. Neuropharmacology. 2016;108:73-81.
Du Jardin KG, Müller HK, Sanchez C, et al. A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex. Eur J Pharmacol. 2016;786:29-35.
Bora E, Harrison BJ, Yücel M, et al. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med. 2013;43(10):2017-2026.
Etkin A, Patenaude B, Song YJ, et al. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. Neuropsychopharmacology. 2015;40(6):1332-1342.
Bennabi D, Haffen E, Van Waes V. Vortioxetine for cognitive enhancement in major depression: from animal models to clinical research. Front Psychiatry. 2019;10:771.
Zuena AR, Maftei D, Alemà GS, et al. Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. Mol Pain. 2018;14:1744806918808987.
Fourrier C, Sampson E, Mills NT, et al. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials. 2018;19(1):447.
Thase ME, Mahableshwarkar AR, Dragheim M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016;26(6):979-993.
Citrome L. Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2016;196:225-233.
Thase ME, Danchenko N, Brignone M, et al. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. Eur Neuropsychopharmacol. 2017;27(8):773-781.
Brignone M, Diamand F, Painchault C, et al. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder. Curr Med Res Opin. 2016;32(2):351-366.
Baune BT, Brignone M, Larsen KG. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution Test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol. 2018;21(2):97-107.
Lenze EJ, Stevens A, Waring JD, et al. Augmenting computerized cognitive training with vortioxetine for age-related cognitive decline: a randomized controlled trial. Am J Psychiatry. 2020;177(6):548-555.
Cumbo E, Cumbo S, Torregrossa S, et al. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer’s Disease Patients with Depressive Symptoms: a 12 Month, Open-Label, Observational Study. J Prev Alzheimers Dis. 2019;6(3):192-197.
Strelnikova IA, Svetkina AA, Minina YuD, et al. Experience with vortioxetine in the treatment of post-stroke depression. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology. Neuropsychiatry, Psychosomatics. 2020;12(1):45-49. (In Russ).
Jacobson W, Zhong W, Nomikos GG, et al. Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis. Curr Med Res Opin. 2020;36(1):117-124.
McIntyre RS, Harrison J, Loft H, et al., The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016;19(10):yw055.
Chokka P, Bougie J, Proulx J, et al. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr. 2019;24(6):616-627.
Florea I, Loft H, Danchenko N, et al. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav. 2017;7(3):e00622.
Cao B, Park C, Subramaniapillai M, et al. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Front Psychiatry. 2019;10:17.
Fagiolini A, Florea I, Loft H, et al. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord. 2021;283:472-479.
Cronquist MC, Florea I, Lindsten A, et al. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol. 2018;32(10):1086-1097.
Liguori C, Ferini-Strambi L, Izzi F, et al. Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. Br J Clin Pharmacol. 2019;85(1):240-244.
Mahableshwarkar AR, Affinito J, Reines EH, et al. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials. CNS Spectr. 2019;14:1-11.
Baldwin DS, Florea I, Jacobsen PL, et al. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord. 2016;206:140-150.
Di Nicola M, Pepe M, Panaccione I, et al. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis. CNS Spectr. 2022;27(1):73-81. https://doi.org/10.1017/S109285292000173X
Nomikos GG, Tomori D, Zhong W, et al. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr. 2017;22(4):348-362.
Freeman MP, Cheng LJ, Moustafa D, et al. Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition. Ann Clin Psychiatry. 2017;29(4):249-257.
Tovilla-Zárate CA, Pérez-Mandujano A, Ramírez-González IR, et al. Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes. Ann Transl Med. 2019;7(22):656.
Russo M, Carrarini C, Dono F, et al. Vortioxetine treatment of depression in Parkinson’s disease[abstract]. Mov Disord. 2019;34(suppl 2). [cited 2021 Dec 20]. https://www.mdsabstracts.org/abstract/vortioxetine-treatment-of-depression-in-parkinsons-disease
Adamo D, Pecoraro G, Coppola N, et al. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: an open-label randomized trial. Oral Dis. 2020;27(4):1022-1041.
Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242-252.131.
Soini E, Hallinen T, Brignone M, et al. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):293-302.